Thrombotic thrombocytopenic pupura (TTP) dinner symposium proceedings

ABSTRACT

Answering TTP was established to engage the thrombotic thrombocytopenic purpura (TTP) community to further the common goals of patient support, education of patients and medical professionals, and the funding of research to improve the treatment and care of TTP patients. Answering TTP convened a dinner symposium on 23 June 2015 in Toronto, Canada during the International Society of Thrombosis and Haemostasis (ISTH) Congress to bring TTP clinicians and research together to highlight the key clinical and research questions in the field. These questions are increasingly important given the recent advances and novel therapies that have or will soon enter clinical study for patients with TTP.

KEYWORDS:

• TTP
• ADAMTS13
• rituximab
• relapse
• complications

Acknowledgments

We would like to thank Debbie Hum for her writing and editing assistance.

Declaration of interest

The Answering TTP Foundation’s TTP Dinner Symposium and related activities were in part sponsored by Baxalta US Inc, Octapharma Canada Inc. and supported by the CIHR Institute of Genetics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.